University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medical Education
  • Medical Education - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medical Education
  • Medical Education - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Clinical benefits of Tocilizumab inCOVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia

    Thumbnail
    Citations
    Altmetric
    Author
    Stephen, S; Park, Y-A; Chrysostomou, A
    Date
    2020-09-17
    Source Title
    Nephrology
    Publisher
    WILEY
    University of Melbourne Author/s
    Chrysostomou, Anastasia
    Affiliation
    Medical Education
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Stephen, S., Park, Y. -A. & Chrysostomou, A. (2020). Clinical benefits of Tocilizumab inCOVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia. NEPHROLOGY, 25 (11), pp.845-849. https://doi.org/10.1111/nep.13767.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254561
    DOI
    10.1111/nep.13767
    Open Access URL
    https://europepmc.org/articles/PMC7436382?pdf=render
    Abstract
    COVID-19 remains a global pandemic with more than 10 million cases and half a million deaths worldwide. The disease manifestations in patients with chronic kidney disease and especially those on haemodialysis are still being understood, with only a few overseas case series, and small observational trials thus far. It appears that the disease is more severe in this patient cohort. Part of the pathophysiology of severe COVID-19 is related to accompanying cytokine release syndrome (CRS). Tocilizumab, an interleukin-6 inhibitor, has been trialled for treatment of CRS in COVID-19, but not yet approved. We present a case of an Australian patient on long-term haemodialysis with severe COVID-19 who was successfully treated with Tocilizumab. The peak of her illness was on day 7, with a C-reactive protein of 624 mg/L (reference < 5 mg/L), ferritin of 5293 ng/mL (reference 30-500 ng/mL), and interleukin-6 level 1959.7 pg/mL, consistent with CRS. She was severely hypoxic on a ventilator, with rising inotropic requirements. With the use of Tocilizumab, there was a significant and immediate response in her inflammatory markers, and she made a steady recovery. The patient was discharged home 6 weeks after presentation.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [53039]
    • Medical Education - Research Publications [598]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors